MyAverix Finance MyAverix Finance

ST · Healthcare

Prostatype Genomics AB (PROGEN)

Diagnostics & Research

Prostatype Genomics AB (PROGEN) is listed on ST in the Healthcare sector. Industry: Diagnostics & Research. As of 2026-05-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for PROGEN

P/E ratio
18.00

Prostatype Genomics AB (PROGEN) — FAQ

What is PROGEN's P/E ratio?

The price-to-earnings (P/E) ratio for Prostatype Genomics AB (PROGEN) is 18.00 (data as of 2026-05-24).

Does Prostatype Genomics AB pay a dividend?

Dividend yield is not available in the current snapshot for Prostatype Genomics AB (PROGEN). Check the MyAverix Finance app for the latest dividend data.

What sector is Prostatype Genomics AB in?

Prostatype Genomics AB (PROGEN) is classified in the Healthcare sector (Diagnostics & Research industry).

What exchange is PROGEN listed on?

PROGEN is listed on ST.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play